[go: up one dir, main page]

WO2010091822A8 - Prodrugs vom typ n-hydroxylierter amidine, guanidine und/oder aminohydrazone zur applikation über die haut - Google Patents

Prodrugs vom typ n-hydroxylierter amidine, guanidine und/oder aminohydrazone zur applikation über die haut Download PDF

Info

Publication number
WO2010091822A8
WO2010091822A8 PCT/EP2010/000715 EP2010000715W WO2010091822A8 WO 2010091822 A8 WO2010091822 A8 WO 2010091822A8 EP 2010000715 W EP2010000715 W EP 2010000715W WO 2010091822 A8 WO2010091822 A8 WO 2010091822A8
Authority
WO
WIPO (PCT)
Prior art keywords
skin
application
aminohydrazone
guanidine
hydroxylated
Prior art date
Application number
PCT/EP2010/000715
Other languages
English (en)
French (fr)
Other versions
WO2010091822A2 (de
WO2010091822A3 (de
Inventor
Rudolf Matusch
Hans-Rainer Hoffmann
Bodo Asmussen
Andreas Koch
Original Assignee
Lts Lohmann Therapie-Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Ag filed Critical Lts Lohmann Therapie-Systeme Ag
Priority to US13/148,422 priority Critical patent/US20110311593A1/en
Priority to BRPI1008538A priority patent/BRPI1008538A2/pt
Priority to JP2011548610A priority patent/JP2012517404A/ja
Priority to CN2010800069562A priority patent/CN102497852A/zh
Priority to EP10707206A priority patent/EP2395971A2/de
Publication of WO2010091822A2 publication Critical patent/WO2010091822A2/de
Publication of WO2010091822A8 publication Critical patent/WO2010091822A8/de
Publication of WO2010091822A3 publication Critical patent/WO2010091822A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft N-hydroxylierte Amidine, Guanidine und Aminohydrazone zur Applikation über die Haut. Insbesondere betrifft die Erfindung transdermale therapeutische Systeme, welche N-hydroxylierte Amidine, Guanidine und Aminohydrazone als Prodrug enthalten, sowie Verfahren zur Herstellung und Verwendung solcher Systeme.
PCT/EP2010/000715 2009-02-10 2010-02-05 Prodrugs vom typ n-hydroxylierter amidine, guanidine und/oder aminohydrazone zur applikation über die haut WO2010091822A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/148,422 US20110311593A1 (en) 2009-02-10 2010-02-05 N-hydroxylated amidine-, guanidine- and/or aminohydrazone-type prodrugs for application on the skin
BRPI1008538A BRPI1008538A2 (pt) 2009-02-10 2010-02-05 profármacos do tipo amidina, guanidina e/ou amino-hidrazona n-hidroxiladas para aplicação sobre a pele
JP2011548610A JP2012517404A (ja) 2009-02-10 2010-02-05 皮膚に適用するためのｎ−ヒドロキシル化アミジン−、グアニジン−及び／又はアミノヒドラゾン−タイプのプロドラッグ
CN2010800069562A CN102497852A (zh) 2009-02-10 2010-02-05 用于经皮施用的n-羟化的脒、胍和氨基腙类型的前药
EP10707206A EP2395971A2 (de) 2009-02-10 2010-02-05 Prodrugs vom typ n-hydroxylierter amidine, guanidine und/oder aminohydrazone zur applikation über die haut

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009008256A DE102009008256A1 (de) 2009-02-10 2009-02-10 Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
DE102009008256.5 2009-02-10

Publications (3)

Publication Number Publication Date
WO2010091822A2 WO2010091822A2 (de) 2010-08-19
WO2010091822A8 true WO2010091822A8 (de) 2011-08-11
WO2010091822A3 WO2010091822A3 (de) 2011-10-13

Family

ID=42173971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/000715 WO2010091822A2 (de) 2009-02-10 2010-02-05 Prodrugs vom typ n-hydroxylierter amidine, guanidine und/oder aminohydrazone zur applikation über die haut

Country Status (8)

Country Link
US (1) US20110311593A1 (de)
EP (1) EP2395971A2 (de)
JP (1) JP2012517404A (de)
KR (1) KR20110120282A (de)
CN (1) CN102497852A (de)
BR (1) BRPI1008538A2 (de)
DE (1) DE102009008256A1 (de)
WO (1) WO2010091822A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011117128A1 (de) * 2011-10-28 2013-05-02 Christian-Albrechts-Universität Zu Kiel Verbindungen zur Therapie der Influenza
CN106361728B (zh) * 2015-07-22 2021-03-26 广东东阳光药业有限公司 经皮吸收制剂及制备经皮吸收制剂的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
MXPA03011196A (es) * 2001-06-08 2004-10-28 Cytovia Inc 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
AU2002350207A1 (en) * 2001-11-19 2003-06-10 Control Delivery Systems, Inc. Topical delivery of codrugs
US20030149406A1 (en) * 2002-02-07 2003-08-07 Lucie Martineau Multi-layer dressing as medical drug delivery system
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
ES2596809T3 (es) * 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
DE102004062614B4 (de) * 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
GB0625648D0 (en) * 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
DE102009008256A1 (de) 2010-08-12
EP2395971A2 (de) 2011-12-21
CN102497852A (zh) 2012-06-13
US20110311593A1 (en) 2011-12-22
BRPI1008538A2 (pt) 2016-03-15
WO2010091822A2 (de) 2010-08-19
JP2012517404A (ja) 2012-08-02
KR20110120282A (ko) 2011-11-03
WO2010091822A3 (de) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
WO2009089494A3 (en) Pharmaceutical compositions
EP2249909A4 (de) Kathetervorrichtungen, -systeme und -verfahren mit steuereingriff
WO2012061537A3 (en) Methods for treating hair loss disorders
EP2271401A4 (de) Topische oder kosmetische mikrostromerzeugende systeme sowie verfahren zu ihrer herstellung und verwendung
HK1134434A1 (en) Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP2240236A4 (de) Hauttherapiesystem
WO2011073279A3 (fr) Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
PL2235098T3 (pl) Spieniona, szczególnie wrażliwa na nacisk masa klejowa, sposób jej wytwarzania oraz jej zastosowanie
AP2011005695A0 (en) Therapeutic antiviral poptides.
ZA201005663B (en) Transdermal therapeutic system having stabilized membrane
PL2168608T3 (pl) Przylepcowa taśma lub arkusz do stosowania na skórę oraz sposób ich wytwarzania
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
EP2729464B8 (de) Cyclopropyl-kondensierte-1,3-thiazepine als bace 1- und/oder bace-2-hemmer
WO2013098416A3 (fr) Composes anti-douleur
WO2014048776A3 (de) Wasseremulgierbare isocyanate mit verbessertem glanz
EP3053485B8 (de) Einstellbarer kindersitz
EP2442864A4 (de) Topische oder kosmetische mikrostromerzeugende systeme sowie verfahren zu ihrer herstellung und verwendung
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2011128262A3 (de) Verwendung fungizider wirkstoffe zur kontrolle von mykosen an palmengewächsen
WO2009158646A8 (en) Therapeutic compounds and related methods of use
WO2010119102A3 (de) Pharmaceutische zusammensetzung enthaltend protonenpumpenhemmer zur behandlung von dermatologischen autoimmunerkrankungen
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2010091822A3 (de) Prodrugs vom typ n-hydroxylierter amidine, guanidine und/oder aminohydrazone zur applikation über die haut
AP2010005479A0 (en) Phospohorous pentoxide producing methods.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080006956.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707206

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010707206

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13148422

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20117018551

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011548610

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1008538

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1008538

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110810